Uijeongbu Eulji University Hospital said Professor Kim Dong-wook's team of hematology department proved that KF1601, a ...

Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

In a second poster, researchers from Greece analyzed front-line TKI selection in CML. They investigated the role of early molecular response (EMR) in the long-term outcome based on the first-line ...

Duker emphasized DURAVYU's differentiation as a sustained release TKI with robust safety and efficacy data, targeting a six-month dosing schedule to improve patient outcomes compared to existing ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC) in a multicohort phase Ia/Ib ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...

In cohort 1, the most common first-line treatments were tyrosine kinase inhibitors (TKI; 78.8%), followed by mammalian target of rapamycin (mTOR) inhibitors (12.4%), the investigators reported in ...